Malte Peters

4.3k total citations · 2 hit papers
12 papers, 2.2k citations indexed

About

Malte Peters is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Malte Peters has authored 12 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Oncology and 2 papers in Genetics. Recurrent topics in Malte Peters's work include PI3K/AKT/mTOR signaling in cancer (6 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Melanoma and MAPK Pathways (2 papers). Malte Peters is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (6 papers), Chronic Lymphocytic Leukemia Research (2 papers) and Melanoma and MAPK Pathways (2 papers). Malte Peters collaborates with scholars based in United States, Switzerland and Canada. Malte Peters's co-authors include David Demanse, Armen S. Manoukian, Richard Binari, Angela Zubel, Howard A. Burris, Qinhua Ru, Jordi Rodón, Johanna C. Bendell, Stefan S. De Buck and Maja J.A. de Jonge and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Cell.

In The Last Decade

Malte Peters

12 papers receiving 2.2k citations

Hit Papers

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Cla... 2011 2026 2016 2021 2011 2013 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
    2011 550 citations Johanna C. Bendell, Jordi Rodón et al. Journal of Clinical Oncology profile →
  2. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study
    2013 499 citations Paolo A. Ascierto, Dirk Schadendorf et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Malte Peters United States 9 1.6k 899 332 288 253 12 2.2k
Lin Pei United States 24 1.3k 0.8× 488 0.5× 217 0.7× 478 1.7× 128 0.5× 48 2.6k
Luca Mologni Italy 32 1.7k 1.1× 942 1.0× 596 1.8× 293 1.0× 403 1.6× 91 3.4k
Sidong Huang Canada 22 1.9k 1.2× 1.2k 1.3× 404 1.2× 621 2.2× 518 2.0× 44 2.9k
Jung-Sik Kim United States 26 1.5k 1.0× 596 0.7× 313 0.9× 406 1.4× 188 0.7× 45 2.2k
Randall Schreck United States 9 1.5k 0.9× 686 0.8× 318 1.0× 469 1.6× 176 0.7× 13 2.3k
Joseph Celestino United States 20 1.5k 0.9× 931 1.0× 213 0.6× 741 2.6× 213 0.8× 46 2.7k
Leonard Girnita Sweden 36 2.5k 1.6× 781 0.9× 352 1.1× 898 3.1× 257 1.0× 72 3.7k
Mari Iida United States 30 1.5k 0.9× 1.3k 1.5× 620 1.9× 429 1.5× 204 0.8× 62 2.8k
David R. Emlet United States 16 1.3k 0.8× 598 0.7× 216 0.7× 231 0.8× 106 0.4× 24 2.1k
Susan E. Moody United States 23 1.8k 1.2× 1.6k 1.7× 347 1.0× 503 1.7× 151 0.6× 29 2.9k

Countries citing papers authored by Malte Peters

Since Specialization
Citations

This map shows the geographic impact of Malte Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malte Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malte Peters more than expected).

Fields of papers citing papers by Malte Peters

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malte Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malte Peters. The network helps show where Malte Peters may publish in the future.

Co-authorship network of co-authors of Malte Peters

This figure shows the co-authorship network connecting the top 25 collaborators of Malte Peters. A scholar is included among the top collaborators of Malte Peters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malte Peters. Malte Peters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
1.
Goldstein, Matthew J., Malte Peters, Barbara L. Weber, & Charles B. Davis. (2020). Optimizing the Therapeutic Window of Targeted Drugs in Oncology: Potency‐Guided First‐in‐Human Studies. Clinical and Translational Science. 14(2). 536–543. 20 indexed citations
2.
Hart, Lori S., JulieAnn Rader, Pichai Raman, et al.. (2016). Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma. Clinical Cancer Research. 23(7). 1785–1796. 57 indexed citations
3.
Münster, Pamela N., Moshe Elkabets, Jill Gilbert, et al.. (2015). Abstract A46: Inhibition of PIK3CA with BYL719 can overcome resistance to cetuximab in squamous cell carcinoma of the head and neck (SCCHN). Molecular Cancer Therapeutics. 14(7_Supplement). A46–A46. 3 indexed citations
4.
Bédard, Philippe L., Josep Tabernero, Filip Jankú, et al.. (2014). A Phase Ib Dose-Escalation Study of the Oral Pan-PI3K Inhibitor Buparlisib (BKM120) in Combination with the Oral MEK1/2 Inhibitor Trametinib (GSK1120212) in Patients with Selected Advanced Solid Tumors. Clinical Cancer Research. 21(4). 730–738. 257 indexed citations
5.
Castel, Pau, Dejan Juric, Helen Won, et al.. (2014). Abstract LB-327: Loss of PTEN leads to clinical resistance to the PI3Kα inhibitor BYL719 and provides evidence of convergent evolution under selective therapeutic pressure. Cancer Research. 74(19_Supplement). LB–327. 5 indexed citations
6.
Ascierto, Paolo A., Dirk Schadendorf, Carola Berking, et al.. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. The Lancet Oncology. 14(3). 249–256. 499 indexed citations breakdown →
7.
Pinzon-Ortiz, Maria, Yan Chen, Xiaoyan Li, et al.. (2013). Targeting PIK3CA mutant breast cancer with the combination of PIK3CA-specific inhibitor, BYL719, and IGF1-R antibody, ganitumab.. Journal of Clinical Oncology. 31(15_suppl). e13525–e13525. 5 indexed citations
8.
Bendell, Johanna C., Jordi Rodón, Howard A. Burris, et al.. (2011). Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 30(3). 282–290. 550 indexed citations breakdown →
9.
Kaiser, Martin, Maren Mieth, Peter Liebisch, et al.. (2008). Serum concentrations of DKK‐1 correlate with the extent of bone disease in patients with multiple myeloma. European Journal Of Haematology. 80(6). 490–494. 124 indexed citations
10.
Kim, Raymond H., Malte Peters, Wei Shi, et al.. (2005). DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell. 7(3). 263–273. 473 indexed citations
11.
Peters, Malte, Carmela DeLuca, Atsushi Hirao, et al.. (2002). Chk2 regulates irradiation-induced, p53-mediated apoptosis in Drosophila. Proceedings of the National Academy of Sciences. 99(17). 11305–11310. 78 indexed citations
12.
Scanga, Sam, Laurent Ruel, Richard Binari, et al.. (2000). The conserved PI3′K/PTEN/Akt signaling pathway regulates both cell size and survival in Drosophila. Oncogene. 19(35). 3971–3977. 160 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lin Pei Breakdown of academic impact, for papers by Luca Mologni Breakdown of academic impact, for papers by Sidong Huang Breakdown of academic impact, for papers by Jung-Sik Kim Breakdown of academic impact, for papers by Randall Schreck Breakdown of academic impact, for papers by Joseph Celestino Breakdown of academic impact, for papers by Leonard Girnita Breakdown of academic impact, for papers by Mari Iida Breakdown of academic impact, for papers by David R. Emlet Breakdown of academic impact, for papers by Susan E. Moody
Rankless by CCL
2026